The focus of WP5 is the development of a proof‐of‐concept core health economic cost‐effectiveness model for the asymptomatic and early symptomatic AD stages (MCI due to AD, mild and moderate AD).

Develop a proof of concept AD cost‐effectiveness and budget impact model for HTA agencies, regulators, service providers, industry, payers and carers (WP5)

Objectives

Identify the specific data and analytical requirements of robust state‐of‐the‐art cost‐effectiveness (C‐E) analysis for Alzheimer Disease (AD) interventions (both symptomatic and disease‐modifying agents) initiated in the asymptomatic and early symptomatic AD stages (Mild cognitive impairment (MCI) due to AD, mild AD and moderate AD). Determine availability and suitability of specifically health economic data (e.g. resource use, unit costs, quality of life, treatment pathways and event probabilities) contributing to Use Case 1
Use relevant RWE datasets to improve the evidence base of long‐term AD C‐E Identify and review existing C‐E models for symptomatic and disease modifying interventions in the asymptomatic and early symptomatic AD stages (MCI due to AD, mild AD and moderate AD) and evaluate against manufacturer, academic and reimbursement requirements and current modelling standards. Evaluate emerging disease trajectory hypotheses across the entire AD spectrum within Use Case 2, in relation to quality of life, treatment costs, resource utilization and HTA modelling requirements in different European jurisdictions
Develop an integrated proof‐of‐concept core health economic model of healthcare use/costs and health outcomes, contributing to Use Case Use model as platform to evaluate medium/long‐term data requirements, requirements for HE models in the asymptomatic and early symptomatic AD stages (MCI due to AD, mild AD and moderate AD), ability to capture heterogeneity across patients and health care systems. The core health economic model shall be adaptable to the needs of various European jurisdictions (e.g. payer, societal perspective) and manufacturer requirements (e.g. modelling pre‐clinical and other stages of Alzheimer Disease)